U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07519525) titled 'A Study of [14C]-LY4064809 in Healthy Participants' on March 30.
Brief Summary: The purpose of this study is to determine in healthy participants the percentage of LY4064809 that enters bloodstream after oral administration. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 21 days, not including screening. Participants will remain in the clinical research center for 14 days.
Study Start Date: March 27
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: LY4064809
Administered orally
DRUG: [14C]-LY4064809
Administered by IV infus...